PL1945243T3 - Zastosowanie kalcytoniny w leczeniu rzs - Google Patents

Zastosowanie kalcytoniny w leczeniu rzs

Info

Publication number
PL1945243T3
PL1945243T3 PL06806679T PL06806679T PL1945243T3 PL 1945243 T3 PL1945243 T3 PL 1945243T3 PL 06806679 T PL06806679 T PL 06806679T PL 06806679 T PL06806679 T PL 06806679T PL 1945243 T3 PL1945243 T3 PL 1945243T3
Authority
PL
Poland
Prior art keywords
calcitonin
treatment
Prior art date
Application number
PL06806679T
Other languages
English (en)
Inventor
Moise Azria
Claus Christiansen
Original Assignee
Novartis Ag
Nordic Bioscience As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Nordic Bioscience As filed Critical Novartis Ag
Publication of PL1945243T3 publication Critical patent/PL1945243T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/609—Amides, e.g. salicylamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL06806679T 2005-11-04 2006-11-03 Zastosowanie kalcytoniny w leczeniu rzs PL1945243T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0522566.9A GB0522566D0 (en) 2005-11-04 2005-11-04 Organic compounds
EP06806679.4A EP1945243B1 (en) 2005-11-04 2006-11-03 Use of calcitonin for the treatment of ra
PCT/EP2006/010576 WO2007051641A1 (en) 2005-11-04 2006-11-03 Use of calcitonin for the treatment of ra

Publications (1)

Publication Number Publication Date
PL1945243T3 true PL1945243T3 (pl) 2015-12-31

Family

ID=35516376

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06806679T PL1945243T3 (pl) 2005-11-04 2006-11-03 Zastosowanie kalcytoniny w leczeniu rzs

Country Status (14)

Country Link
US (2) US8835389B2 (pl)
EP (1) EP1945243B1 (pl)
JP (3) JP2009514912A (pl)
KR (2) KR101435689B1 (pl)
CN (1) CN101300025A (pl)
AU (1) AU2006310702B2 (pl)
BR (1) BRPI0618193A2 (pl)
CA (1) CA2632207C (pl)
ES (1) ES2547379T3 (pl)
GB (1) GB0522566D0 (pl)
PL (1) PL1945243T3 (pl)
PT (1) PT1945243E (pl)
RU (1) RU2453330C2 (pl)
WO (1) WO2007051641A1 (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0522566D0 (en) * 2005-11-04 2005-12-14 Novartis Ag Organic compounds
US10842813B2 (en) 2007-02-26 2020-11-24 Heartbeet Ltd Compositions of nitrates and methods of use thereof
ES2618655T3 (es) 2007-02-26 2017-06-21 Heartbeet Ltd. Composición que mejora el rendimiento y uso de la misma
US10821132B2 (en) 2007-02-26 2020-11-03 Heartbeet Ltd Compositions of nitrates and methods of use thereof
US11759477B2 (en) 2007-02-26 2023-09-19 Heartbeet Ltd. Compositions of nitrates and methods of use thereof
US20120071410A1 (en) 2010-09-21 2012-03-22 Unigene Laboratories Inc. Calcitonin products and therapies for treating inflammatory or degenerative diseases
KR20150116665A (ko) 2014-04-08 2015-10-16 현대모비스 주식회사 프라이머리 옵틱 렌즈 및 이를 구비한 차량용 램프
CN104888198A (zh) * 2015-04-21 2015-09-09 徐志强 降钙素在制造延缓脑老化药物的新用途
KR102336516B1 (ko) 2017-03-27 2021-12-06 각코호진 니이가타기쥬츠카가쿠가쿠엔 변이형 2-데옥시-실로-이노소스 합성효소
US11274158B2 (en) * 2018-01-30 2022-03-15 Flagship Pioneering Innovations V, Inc. Methods and compositions for treating inflammatory or autoimmune diseases or conditions using calcitonin receptor activators
CN112494637B (zh) * 2020-12-08 2023-05-23 中山大学附属第七医院(深圳) 一种鲑鱼降钙素在制备用于治疗抑郁症药物中的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2016580C1 (ru) * 1990-12-10 1994-07-30 Ижевский Государственный Медицинский Институт Способ лечения осложненного ревматоидного артрита
US5912014A (en) * 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
JP4588221B2 (ja) * 1999-04-05 2010-11-24 エミスフェアー・テクノロジーズ・インク 活性剤を送達するための二ナトリウム塩、一水和物、およびエタノール溶媒和物
US7049283B2 (en) * 2000-12-06 2006-05-23 Novartis Ag Pharmaceutical compositions for the oral delivery of pharmacologically active agents
AU2002344371B2 (en) 2001-06-01 2006-06-29 Novartis Ag Orally administering parathyroid hormone and calcitonin
RU2322256C2 (ru) 2001-08-17 2008-04-20 Новартис Аг 5-cnac в качестве агента для пероральной доставки фрагментов паратироидного гормона
AU2002352974A1 (en) * 2001-11-29 2003-06-10 Emisphere Technologies, Inc. Formulations for oral administration of cromolyn sodium
AU2003213266A1 (en) 2002-03-06 2003-09-22 Smithkline Beecham Corporation Condensed heterocyclic compounds as calcitonin agonists
TWI307279B (en) * 2002-08-01 2009-03-11 Novartis Ag Oral administration of calcitonin
CA2529604C (en) * 2003-07-11 2012-05-08 Novartis Ag Orally dosed pharmaceutical compositions comprising a delivery agent in micronized form
AU2004262906B2 (en) * 2003-07-23 2008-04-03 Nordic Bioscience A/S Use of calcitonin in osteoarthritis
US7184851B2 (en) * 2005-06-28 2007-02-27 Taiwan Semiconductor Manufacturing Co., Ltd. Method of providing cassettes containing control wafers to designated processing tools and metrology tools
GB0522566D0 (en) * 2005-11-04 2005-12-14 Novartis Ag Organic compounds
WO2009019307A2 (en) * 2007-08-09 2009-02-12 Novartis Ag Oral calcitonin compositions and applications thereof

Also Published As

Publication number Publication date
US8835389B2 (en) 2014-09-16
KR101435689B1 (ko) 2014-09-01
EP1945243B1 (en) 2015-07-15
GB0522566D0 (en) 2005-12-14
JP2009514912A (ja) 2009-04-09
PT1945243E (pt) 2015-10-12
RU2008122185A (ru) 2009-12-10
JP2017061572A (ja) 2017-03-30
CA2632207C (en) 2014-12-23
AU2006310702B2 (en) 2009-11-12
JP6118107B2 (ja) 2017-04-19
EP1945243A1 (en) 2008-07-23
CA2632207A1 (en) 2007-05-10
KR20140041843A (ko) 2014-04-04
KR20080063819A (ko) 2008-07-07
BRPI0618193A2 (pt) 2011-08-23
JP2013075908A (ja) 2013-04-25
AU2006310702A1 (en) 2007-05-10
ES2547379T3 (es) 2015-10-05
CN101300025A (zh) 2008-11-05
WO2007051641A1 (en) 2007-05-10
US20080226737A1 (en) 2008-09-18
US20120219603A1 (en) 2012-08-30
RU2453330C2 (ru) 2012-06-20

Similar Documents

Publication Publication Date Title
PT1945243E (pt) Utilização da calcitonina para o tratamento da ar
HUE054365T2 (hu) Bór-ftalidok terápiás alkalmazásra
IL208607A0 (en) Improved nanobodiestm for the treatment of aggregation-mediated disorders
HK1205935A1 (en) Non-lithotripsic kidney-stone therapy
PL1685834T3 (pl) Zastosowanie kwasu pinolenowego do leczenia otyłości
HK1161122A1 (en) Use of 24-norudca 24-norudca
GB0516068D0 (en) Well treatment
GB0525540D0 (en) New treatment
GB0517387D0 (en) Combinations for the treatment of cancer
GB0511769D0 (en) Treatment
GB0501655D0 (en) Therapeutic use
IL187792A0 (en) 4-anilino-3-quinolinecarbonitriles for the treatment of cancer
EP1931370A4 (en) USE OF DES-ASPARTATE-ANGIOTENSIN I
GB0502171D0 (en) Well treatment
IL178907A0 (en) Use of sulglicotide for the treatment of mucositis
ZA200805522B (en) Dioxoiane dérivates for the treatment of cancer
IL185691A0 (en) Novel compounds derived from 5-thioxylose and therapeutic use thereof
EP1841457A4 (en) TARGET APHERESIS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
GB0602857D0 (en) The treatment of sialorrhoea
GB0517386D0 (en) Combinations for the treatment of cancer
TJ20050863A (en) The way of narcotism treatment
GB0602858D0 (en) The treatment of sialorrhoea
GB0602855D0 (en) The Treatment Of Sialorrhoea
GB0518003D0 (en) Treatment of hepatatis c
GB0501657D0 (en) Therapeutic use